Skip to main content

Table 1 Comparison of Baseline Demographics and Characteristics Between African American and Caucasian Subjects in the CONFIRMS Trial

From: African American patients with gout: efficacy and safety of febuxostat vs allopurinol

Variable African American N = 228 Caucasian N = 1,863 p valuea
Gender, n (%)    
   Male 204 (89.5) 1,768 (94.9) < 0.001
   Female 24 (10.5) 95 (5.1)  
Age (years)    
   Mean ± SD 53.2 ± 10.45 53.0 ± 11.80 0.799
Body Mass Index (kg/m 2 )    
   Mean ± SD 34.0 ± 7.47 32.8 ± 6.09 0.006
Alcohol Use, n (%)    
   Non-/Ex-drinker 88 (38.6) 563 (30.2) 0.010
   Drinker (1-14 drinks/week) 140 (61.4) 1,300 (69.8)  
Tobacco Use, n (%)    
   Non-/Ex-tobacco User 177 (77.6) 1,528 (82.0) 0.107
   Tobacco User 51 (22.4) 335 (18.0)  
Serum Urate (mg/dL)    
   Mean ± SD 9.8 ± 1.24 9.5 ± 1.16 < 0.001
Years with Gout    
   Mean ± SD 10.4 ± 8.28 11.8 ± 9.49 0.030
Tophi Present, n (%)    
   No 169 (74.1) 1,482 (79.5) 0.058
   Yes 59 (25.9) 381 (20.5)  
Renal Function, b n (%)    
   Moderately Impaired 69 (30.3) 299 (16.0) < 0.001
   Mildly Impaired 109 (47.8) 884 (47.5)  
   Normal 50 (21.9) 680 (36.5)  
Medical History, n (%)    
   Any cardiovascular disease 170 (74.6) 1,024 (55.0) < 0.001
   Hypertension 165 (72.4) 937 (50.3) < 0.001
   Coronary artery disease 25 (11.0) 161 (8.6) 0.245
   Cardiac arrhythmia 19 (8.3) 202 (10.8) 0.245
   Diabetes 57 (25.0) 229 (12.3) < 0.001
   Hypercholesterolemia 19 (8.3) 130 (7.0) 0.454
   Hyperlipidemia 83 (36.4) 776 (41.7) 0.128
   Use of low-dose aspirin (≤ 325 mg daily) 40 (17.5) 343 (18.4) 0.749
  1. a p values determined from analysis of variance model for age, body mass index, baseline serum urate, and years with gout, and by Fisher's exact test for all other variables.
  2. bModerate baseline renal impairment: estimated creatinine clearance (eCLcr) 30 to < 60 mL/min; mild baseline renal impairment: eCLcr 60 to < 90 mL/min; normal: eCLcr ≥ 90 mL/min.